Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 5/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699250 | 0.98 | DNM2 (0.44) | DNM2TLR8HCAR3HRH4SOAT1 | |
| SCHEMBL574419 | 0.95 | TLR8 (0.46) | DNM2TLR8HCAR3HRH4LMNA | |
| SCHEMBL15688595 | 0.87 | HCAR3 (0.37) | TLR8HCAR3HRH4LMNASMN1; SMN2 | |
| SCHEMBL7662000 | 0.81 | HRH3 (0.47) | TLR8HRH4 | |
| SCHEMBL7653336 | 0.81 | KDM4D (0.46) | — | |
| SCHEMBL7119883 | 0.79 | HRH3 (0.36) | HRH4LMNA | |
| SCHEMBL7121214 | 0.76 | CYP2C19 (0.56) | DNM2HRH4 | |
| SCHEMBL10684352 | 0.73 | KDM4E (0.51) | DNM2TLR8HCAR3SMN1; SMN2 | |
| SCHEMBL30449687 | 0.71 | CYP2C19 (0.59) | TLR8HCAR3SOAT1ALOX12S1PR2 | |
| SCHEMBL3797836 | 0.71 | KDM4E (0.54) | DNM2TLR8HCAR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1715862-A1 | KINASE INHIBITORS | Devgen NV (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | DNM2 636/4885TLR8 3876/4885HCAR3 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.